Our top pick for
ChemoCentryx Inc is a biotechnology business based in the US. ChemoCentryx shares (CCXI) are listed on the NASDAQ and all prices are listed in US Dollars. ChemoCentryx employs 133 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$34.57|
|52-week range||$9.53 - $70.29|
|50-day moving average||$20.53|
|200-day moving average||$21.22|
|Wall St. target price||$70.88|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.77|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||0.29%|
|1 month (2021-09-24)||89.95%|
|3 months (2021-07-23)||140.57%|
|6 months (2021-04-23)||-24.68%|
|1 year (2020-10-23)||-41.21%|
|2 years (2019-10-23)||349.54%|
|3 years (2018-10-23)||211.16%|
|5 years (2016-10-21)||453.12%|
|Revenue TTM||$21.6 million|
|Gross profit TTM||$-12,991,000|
|Return on assets TTM||-15.04%|
|Return on equity TTM||-32.7%|
|Market capitalisation||$2.4 billion|
TTM: trailing 12 months
There are currently 3.9 million ChemoCentryx shares held short by investors – that's known as ChemoCentryx's "short interest". This figure is 4.5% up from 3.7 million last month.
There are a few different ways that this level of interest in shorting ChemoCentryx shares can be evaluated.
ChemoCentryx's "short interest ratio" (SIR) is the quantity of ChemoCentryx shares currently shorted divided by the average quantity of ChemoCentryx shares traded daily (recently around 1.6 million). ChemoCentryx's SIR currently stands at 2.38. In other words for every 100,000 ChemoCentryx shares traded daily on the market, roughly 2380 shares are currently held short.
However ChemoCentryx's short interest can also be evaluated against the total number of ChemoCentryx shares, or, against the total number of tradable ChemoCentryx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ChemoCentryx's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 ChemoCentryx shares in existence, roughly 60 shares are currently held short) or 0.0777% of the tradable shares (for every 100,000 tradable ChemoCentryx shares, roughly 78 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ChemoCentryx.
Find out more about how you can short ChemoCentryx stock.
We're not expecting ChemoCentryx to pay a dividend over the next 12 months.
Over the last 12 months, ChemoCentryx's shares have ranged in value from as little as $9.53 up to $70.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ChemoCentryx's is 1.4148. This would suggest that ChemoCentryx's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
ChemoCentryx, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.